Cargando…

Carbetocin in comparison with oxytocin in several dosing regimens for the prevention of uterine atony after elective caesarean section in the Netherlands

PURPOSE: The aim of the study was to compare the prophylactic effects of carbetocin with those of oxytocin for the prevention of uterine atony in patients undergoing elective caesarean section (CS) in the Netherlands. The primary endpoint was the need for additional uterotonic medication. METHODS: E...

Descripción completa

Detalles Bibliográficos
Autores principales: Holleboom, C. A. G., van Eyck, J., Koenen, S. V., Kreuwel, I. A. M., Bergwerff, F., Creutzberg, E. C., Bruinse, H. W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3655222/
https://www.ncbi.nlm.nih.gov/pubmed/23329341
http://dx.doi.org/10.1007/s00404-012-2693-8
_version_ 1782269848909250560
author Holleboom, C. A. G.
van Eyck, J.
Koenen, S. V.
Kreuwel, I. A. M.
Bergwerff, F.
Creutzberg, E. C.
Bruinse, H. W.
author_facet Holleboom, C. A. G.
van Eyck, J.
Koenen, S. V.
Kreuwel, I. A. M.
Bergwerff, F.
Creutzberg, E. C.
Bruinse, H. W.
author_sort Holleboom, C. A. G.
collection PubMed
description PURPOSE: The aim of the study was to compare the prophylactic effects of carbetocin with those of oxytocin for the prevention of uterine atony in patients undergoing elective caesarean section (CS) in the Netherlands. The primary endpoint was the need for additional uterotonic medication. METHODS: Each of the five participating Dutch hospitals treated 50–100 term patients with 100 μg of intravenous carbetocin on prescription. Each centre retrieved charts of 250 patients treated with oxytocin according to the hospital’s policy for the prevention of uterine atony (oxytocin bolus 5 IU, bolus 10 IU or bolus 5 IU followed by 10 IU in 2 h). RESULTS: In the carbetocin group 462 subjects were included and in the oxytocin group 1,122. The proportion of subjects needing additional uterotonic treatment was 3.1 % (95 % CI 1.7–5.1 %) after carbetocin and 7.2 % (5.8–8.9 %) after oxytocin; relative risk 0.41 (0.19–0.85); p = 0.0110. Carbetocin was most effective compared with the oxytocin 5 IU bolus subgroup with less need for additional uterotonic medication (3.1 vs. 9.3 %, p = 0.0067) and blood transfusions (2.2 vs. 3.6 %, p = 0.0357). CONCLUSIONS: Compared with oxytocin, prophylaxis of uterine atony with carbetocin after an elective CS diminished the need for additional uterotonics by more than 50 %.
format Online
Article
Text
id pubmed-3655222
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Springer-Verlag
record_format MEDLINE/PubMed
spelling pubmed-36552222013-05-16 Carbetocin in comparison with oxytocin in several dosing regimens for the prevention of uterine atony after elective caesarean section in the Netherlands Holleboom, C. A. G. van Eyck, J. Koenen, S. V. Kreuwel, I. A. M. Bergwerff, F. Creutzberg, E. C. Bruinse, H. W. Arch Gynecol Obstet Maternal-Fetal Medicine PURPOSE: The aim of the study was to compare the prophylactic effects of carbetocin with those of oxytocin for the prevention of uterine atony in patients undergoing elective caesarean section (CS) in the Netherlands. The primary endpoint was the need for additional uterotonic medication. METHODS: Each of the five participating Dutch hospitals treated 50–100 term patients with 100 μg of intravenous carbetocin on prescription. Each centre retrieved charts of 250 patients treated with oxytocin according to the hospital’s policy for the prevention of uterine atony (oxytocin bolus 5 IU, bolus 10 IU or bolus 5 IU followed by 10 IU in 2 h). RESULTS: In the carbetocin group 462 subjects were included and in the oxytocin group 1,122. The proportion of subjects needing additional uterotonic treatment was 3.1 % (95 % CI 1.7–5.1 %) after carbetocin and 7.2 % (5.8–8.9 %) after oxytocin; relative risk 0.41 (0.19–0.85); p = 0.0110. Carbetocin was most effective compared with the oxytocin 5 IU bolus subgroup with less need for additional uterotonic medication (3.1 vs. 9.3 %, p = 0.0067) and blood transfusions (2.2 vs. 3.6 %, p = 0.0357). CONCLUSIONS: Compared with oxytocin, prophylaxis of uterine atony with carbetocin after an elective CS diminished the need for additional uterotonics by more than 50 %. Springer-Verlag 2013-01-18 2013 /pmc/articles/PMC3655222/ /pubmed/23329341 http://dx.doi.org/10.1007/s00404-012-2693-8 Text en © The Author(s) 2013 https://creativecommons.org/licenses/by/2.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Maternal-Fetal Medicine
Holleboom, C. A. G.
van Eyck, J.
Koenen, S. V.
Kreuwel, I. A. M.
Bergwerff, F.
Creutzberg, E. C.
Bruinse, H. W.
Carbetocin in comparison with oxytocin in several dosing regimens for the prevention of uterine atony after elective caesarean section in the Netherlands
title Carbetocin in comparison with oxytocin in several dosing regimens for the prevention of uterine atony after elective caesarean section in the Netherlands
title_full Carbetocin in comparison with oxytocin in several dosing regimens for the prevention of uterine atony after elective caesarean section in the Netherlands
title_fullStr Carbetocin in comparison with oxytocin in several dosing regimens for the prevention of uterine atony after elective caesarean section in the Netherlands
title_full_unstemmed Carbetocin in comparison with oxytocin in several dosing regimens for the prevention of uterine atony after elective caesarean section in the Netherlands
title_short Carbetocin in comparison with oxytocin in several dosing regimens for the prevention of uterine atony after elective caesarean section in the Netherlands
title_sort carbetocin in comparison with oxytocin in several dosing regimens for the prevention of uterine atony after elective caesarean section in the netherlands
topic Maternal-Fetal Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3655222/
https://www.ncbi.nlm.nih.gov/pubmed/23329341
http://dx.doi.org/10.1007/s00404-012-2693-8
work_keys_str_mv AT holleboomcag carbetocinincomparisonwithoxytocininseveraldosingregimensforthepreventionofuterineatonyafterelectivecaesareansectioninthenetherlands
AT vaneyckj carbetocinincomparisonwithoxytocininseveraldosingregimensforthepreventionofuterineatonyafterelectivecaesareansectioninthenetherlands
AT koenensv carbetocinincomparisonwithoxytocininseveraldosingregimensforthepreventionofuterineatonyafterelectivecaesareansectioninthenetherlands
AT kreuweliam carbetocinincomparisonwithoxytocininseveraldosingregimensforthepreventionofuterineatonyafterelectivecaesareansectioninthenetherlands
AT bergwerfff carbetocinincomparisonwithoxytocininseveraldosingregimensforthepreventionofuterineatonyafterelectivecaesareansectioninthenetherlands
AT creutzbergec carbetocinincomparisonwithoxytocininseveraldosingregimensforthepreventionofuterineatonyafterelectivecaesareansectioninthenetherlands
AT bruinsehw carbetocinincomparisonwithoxytocininseveraldosingregimensforthepreventionofuterineatonyafterelectivecaesareansectioninthenetherlands